Summary

The study examined 42 patients with idiopathic pulmonary fibrosis and reported lower predicted biological age across six independent proteomic clocks after treatment. The findings are biomarker results and do not establish that the drug reverses ageing or improves longevity.

Why it matters

The work provides a clinically tested example of AI-discovered targets and AI-designed molecules being evaluated with biological-age measures, while illustrating the gap between biomarker signals and validated therapeutic outcomes.

Sources